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Infection with Burkholderia cepacia complex in patients with cystic fibrosis (CF) results in highly variable
clinical outcomes. The purpose of this study was to determine if there are genomovar-specific disparities in
transmission and disease severity. B. cepacia complex was recovered from 62 patients with CF on1 occasions
(genomovar III, 46 patients; genomovar II [B. multivorans], 19 patients; genomovar IV [B. stabilis], 1 patient;
genomovar V [B. vietnamiensis], 1 patient; and an unclassified B. cepacia complex strain, 1 patient). Patient-
to-patient spread was observed with B. cepacia genomovar III, but not with B. multivorans. Genomovar III
strains replaced B. multivorans in 6 patients. Genomovar III strains were also associated with a poor clinical
course and high mortality. Infection control practices should be designed with knowledge about B. cepacia
complex genomovar status; patients infected with transmissible genomovar III strains should not be cohorted
with patients infected with B. multivorans and other B. cepacia genomovars.
The gram-negative bacterium Burkholderia (formerly
Pseudomonas) cepacia [1] is a problematic pulmonary
pathogen in patients with cystic fibrosis (CF). The or-
ganism is highly virulent in certain patients with CF
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[2], and there is substantial evidence that B. cepacia
may spread from one patient with CF to another, both
within and outside the hospital [3, 4]. Spread may be
dependent on a number of risk factors, including bac-
terial strain type [5–9], patient behavior [9], use of
contaminated therapeutic devices [10], and treatment
center infection control practices [11]. To reduce spread
of the organism, isolation or segregation of patients
who are infected with B. cepacia has been recommended
[4, 12]. Recent changes in the taxonomy of the species
B. cepacia [13] have further complicated our under-
standing of the epidemiology of B. cepacia respiratory
infection in patients with CF. Vandamme et al. [13]
demonstrated that 5 distinct genomic species (referred
to as “genomovars” [14]) are present among strains
classified as B. cepacia. Three of the genomovars have
been assigned species designation because of unique
phenotypic features (genomovar II, Burkholderia multi-
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vorans [13]; genomovar IV, Burkholderia stabilis [15], and gen-
omovar V, Burkholderia vietnamiensis [13]). Until differential
tests are found, the remaining 2 groups are referred to as gen-
omovars I and III, and all 5 genomovars are grouped in the B.
cepacia complex [13].
Infection of patients with CF with B. cepacia complex is
associated with a poor prognosis [16], but the risk attributable
to infection with each genomovar and species has not been
determined. Understanding these risks is vital for CF treatment
centers to develop rational infection control policies and ther-
apeutic approaches for B. cepacia complex–infected individuals.
The epidemiology of infection with B. cepacia complex is poorly
understood, in part because of difficulties with identification
of B. cepacia [17] and the complexities of genomovar analysis
[13]. Retrospective examination of strain collections suggests
that the propensity of B. cepacia strains to spread among pa-
tients with CF is mainly associated with strains of genomovar
III, although outbreaks linked to infection with B. multivorans
strains in the United Kingdom and France have been reported
[13, 18, 19]. The clinical outcomes of B. cepacia infections in
patients with CF may also differ widely [20].
We speculated that strain and genomovar heterogeneity ac-
counts for the extraordinary clinical variation among infected
patients with CF. The purpose of this study was to characterize
the natural history of infection with strains of the different
genomovars and to determine if there is genomovar-specific
disparity in transmission and disease severity. We have collected
all isolates of B. cepacia from patients with CF who have at-
tended treatment centers in Vancouver since 1981. All isolates
were evaluated for genomovar status by recA gene polymor-
phism [21] to complement conventional genomovar testing
[13]. In this study we report on a systematic study of the natural
history of B. cepacia complex infection in a defined CF patient
population.
METHODS
Study population. B. cepacia isolates were recovered from
patients with CF attending either the pediatric clinic (British
Columbia’s Children’s Hospital) or adult clinic (St. Paul’s Hos-
pital, or Shaughnessy Hospital until September 1993) in Van-
couver. Data collected from June 1981 through June 1998 are
presented in this study. Approximately 450 patients with CF
were treated during this period. A total of 281 B. cepacia com-
plex isolates were recovered from 62 patients. Sputum cultures
were performed at every clinic visit (3- to 6-month intervals)
for each patient.
Microbiology and molecular epidemiology. B. cepacia iso-
lates were cultured from sputum, identified, and stored exactly
as described elsewhere [7, 17]. A patient was considered free
of B. cepacia if 3 consecutive cultures over a period 13 weeks
or 2 separate hospitalizations failed to yield B. cepacia complex
bacteria (referred to as “B. cepacia–negative” below). Infection
with Pseudomonas aeruginosa was also recorded for each pa-
tient, and culture and identification of this organism were car-
ried out as described elsewhere [22]. Each B. cepacia complex
isolate was genetically typed by random amplified polymorphic
DNA (RAPD) analysis as described elsewhere [7, 22]. One iso-
late representative of each RAPD-defined strain type was also
genetically fingerprinted by macrorestriction of whole genomic
DNA with the restriction enzyme SpeI, followed by pulsed-field
gel electrophoresis (PFGE) [23, 24]. PFGE fingerprints were
compared by eye and computer software (Molecular Analyst
Fingerprinting; BioRad), and Tenover’s criteria [25] were used
to define a strain type.
Clusters defined by each method correlated perfectly, and a
numerical strain type (ST) was assigned to 2 isolates that
were grouped by fingerprint analysis. Isolates producing genetic
fingerprints that did not match others within the strain col-
lection were designated as unique. All B. cepacia complex iso-
lates were also tested for the presence of the B. cepacia epidemic
strain marker and cable pilus gene (cblA) as described elsewhere
[8].
Genomovar analysis. The genomovar of each genetically
defined strain was initially determined by use of conventional
whole-cell protein electrophoresis as described elsewhere [13].
Final genomovar status was then confirmed by analysis of the
B. cepacia complex recA gene [21].
Statistical analysis. Comparison of the mean age of pa-
tients at the time of B. cepacia complex acquisition and mean
duration of colonization was performed by independent t tests.
For all data, the meanSE is shown.
RESULTS
Prevalence of B. cepacia complex infection in patients with
CF from Vancouver. B. cepacia complex isolates were recov-
ered from 62 patients with CF during the study period, for a
prevalence of 13% (62 of 450 patients). In total, 68 different
B. cepacia complex isolates were recovered, and 11 genomovar
was recovered from each of 6 of the 62 patients. Genomovar
III strains were recovered from 46 patients (74% of B. cepa-
cia–infected patients). B. multivorans (genomovar II) was re-
covered from 19 patients (30% of B. cepacia–infected patients).
Of the remaining patients, 1 was chronically infected with a B.
stabilis (genomovar IV) strain (7 isolates over 4 years); a single
culture was positive for B. vietnamiensis (genomovar V) for the
second, and a B. cepacia complex strain that could not be
subclassified by conventional or molecular analysis [13, 21] was
recovered on 2 occasions from the third. Data for patients with
CF who were newly infected with B. cepacia complex bacteria
were analyzed in 5-year blocks and are presented in figure 1.
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Figure 1. Prevalence of infection with each Burkholderia cepacia com-
plex genomovar among patients with cystic fibrosis over the study period.
Patients newly infected with genomovar III (column III), B. multivorans
(column Bm) , and other B. cepacia complex genomovars (B. stabilis, B.
vietnamiensis, or an unclassified genomovar; column O), are plotted by
5-year blocks. Blocks denoting patients infected with a strain shared
by 2 patients are shaded to indicate the occurrences of patient-to-
patient transmission.
Molecular epidemiology of B. cepacia genomovar III. Twelve
strain types were found among the 46 patients with CF who were
infected with B. cepacia genomovar III. Four genomovar III strain
types (ST01, ST02, ST04, and ST06) were each recovered from
6 patients and were presumed to have spread from patient to
patient. The genetic fingerprints obtained by PFGE of these pre-
dominant strain types are shown in figure 2A. Strain type ST02
was cblA-positive and belonged to the major CF lineage (ET12)
that infects patients in the United Kingdom and Canada [6, 18].
All but 1 of the 9 patients were infected with the ET12 strain
before moving to British Columbia. The remaining 3 transmis-
sible genomovar III strain types were cblA-negative. All strains
that had spread among patients encoded the B. cepacia epidemic
strain marker and also belonged to the recA genomovar III-A
lineage [21]. This B. cepacia complex phylogenetic group was
dominant within the Vancouver CF patient population, account-
ing for 82% of genomovar III infections and 61% of all cases
involving B. cepacia complex.
Socializing among patients may have contributed to the
spread of the 4 genomovar III-A strain types. Evidence of this
mode of spread was observed in the epidemiology of B. cepacia
strain ST04. A total of 6 patients were considered to be a “social
cohort” and interacted with one another extensively, inside and
outside of the hospital. The strain was acquired by all 6 patients
within a 3-year period. Evidence of spread due to social contact
was also observed for genomovar III strain ST06. For 7 years,
this strain was recovered from only 1 patient. During adoles-
cence, he socialized in the hospital extensively with a number
of other contacts with CF; 3 of these contacts subsequently
became infected with strain ST06.
Segregation (separate rooms and treatment areas) and in-
tensive education of B. cepacia–infected patients with CF and
caregivers were introduced in November 1995 at the Vancouver
treatment centers. New acquisitions of transmissible genomovar
III strains ST01, ST02, ST04, and ST06 were significantly re-
duced in the ensuing 2 years (figure 1). The majority of gen-
omovar III infections that occurred after November 1995 were
caused by genetically unique strains (figure 1).
Genomovar III-B strains were recovered from 6 patients,
most of whom were infected with genetically distinct strains
that did not spread to other patients during the study period.
Patients 21 and 34 were each transiently culture-positive for
the same genomovar III-B strain type (ST73). However, the
isolates were recovered only once from each patient, 3 years
apart. Both patients attended the pediatric treatment center,
but they had no known contact with one another. The unique
genomovar III-B strain recovered from patient 27 was the only
genomovar III strain that lacked the B. cepacia epidemic strain
marker DNA. No deaths were associated with strains of recA
subgroup genomovar III-B.
Molecular epidemiology of B. multivorans. Seventeen dif-
ferent strains were recovered from 19 patients with CF who were
infected with B. multivorans. The diversity in B. multivorans ge-
netic fingerprints is shown in figure 2B. Only 2 strain types, ST49
and ST15, were recovered from 11 patient. B. multivorans strain
ST49 (figure 2B) was transiently recovered from patients 51 and
52, who were siblings; both siblings lost this strain and were later
classified as B. cepacia complex–negative. B. multivorans type
ST15 was recovered from patients 15 and 41 only once each.
Among the remaining 15 B. multivorans strains recovered from
patients with CF, there was no evidence of spread during the 17-
year study period. None of the B. multivorans strains examined
harbored the cable pilus subunit gene or B. cepacia epidemic
strain marker DNA.
Mortality associated with B. cepacia genomovar III and B.
multivorans infection. A summary of the epidemiological
characteristics of patients with CF infected with genomovar III
or B. multivorans is presented in table 1. Patients with geno-
movar III infection were significantly older than those infected
with B. multivorans. The mean duration of infection recorded
within the study period was not statistically different for the 2
groups of patients. However, the number of patients who were
transiently infected with B. multivorans (10 out of 19 patients)
exceeded the number transiently infected with genomovar III
strains (9 out of 46), which generally caused chronic infection.
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Figure 2. Pulsed-field gel electrophoretic (PFGE) fingerprints of Burkholderia cepacia complex bacteria. A, macorestriction fingerprints obtained from
each of the predominant B. cepacia genomovar III strain types, ST01, ST02, ST04, and ST06. Strain fingerprints are shown for 3 patients infected
with each major genomovar III strain, and the genetic type is indicated below each conserved group of 3 fingerprints. B, PFGE fingerprints for 11
strains of B. multivorans recovered from 12 patients. Strain type ST49 was transiently recovered from 2 patients (numbers 51 and 52), who were
siblings. Patients 14 and 32 (indicated by asterisks) were initially infected with distinct B. multivorans strains (B); genomovar III strain ST04 was
subsequently recovered from each of these patients (A).
The mean duration of P. aeruginosa infection prior to culture
of B. cepacia complex was similar for the 2 groups. However,
the number of patients infected with P. aeruginosa prior to
infection with B. cepacia complex bacteria was marginally
greater for cases involving genomovar III (35 out of 46 patients)
than for those involving B. multivorans (9 out of 19).
Mortality associated with B. multivorans infection was min-
imal in comparison with that associated with genomovar III
(only 3 deaths occurred among patients with CF from whom
B. multivorans was recovered). Two patients were infected with
both B. multivorans and a genomovar III strain at the time of
death. The third patient was culture-positive for B. multivorans
once and died 4 years later, after being consistently culture-
negative for B. cepacia complex. Of the 46 patients with CF
from whom B. cepacia genomovar III strains were recovered,
20 died, and all of them harbored transmissible strains of the
genomovar III-A lineage [21] (table 1). Eight pediatric patients
died when infected with genomovar III-A strains before age 18
years; 12 adult patients died when infected after age 18 years.
Six patients presented with symptoms of “B. cepacia syndrome”
[2] prior to death (table 1). Of the remaining patients who
died, all presented with terminal pulmonary decompensation
and uncontrollable lung disease prior to death (table 1). The
highest mortality was associated with genomovar III-A strain
type ST04 (table 1). Fewer deaths in our patient population
were associated with the highly transmissible ET12 cblA strain
type ST02 (table 1). No deaths were associated with infection
by genomovar III-A strain type ST06 (table 1), even though
this strain was associated with significant patient-to-patient
spread.
Replacement of B. multivorans by genomovar III. Six
patients were initially infected with B. multivorans, and each
patient carried a unique strain (figure 2); in each case, the
patients subsequently were infected with a genomovar III strain.
Two of these patients were subsequently infected by a geno-
movar III-A strain of type ST04; one of them died shortly
thereafter. Four other patients acquired strain ST04 by social
interaction with the initial 2 infected patients. However, none
of these patients acquired infection with the B. multivorans
strains carried by these 2 patients, despite the fact that 1 of
these patients remained coinfected with the B. multivorans
strain and genomovar III strain ST04 for the next 2 years, until
death. One patient acquired genomovar III strain ST01 4 years
after testing positive for B. multivorans infection; this patient
underwent double lung transplantation, survived B. cepacia sep-
ticemia, and is currently alive. Of the 3 remaining B. multi-
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Table 1. Summary of epidemiological characteristics of patients with cystic
fibrosis who had Burkholderia cepacia genomovar III or Burkholderia multivorans
infection.
Parameter
Mean valueSD or no. (%) of patients
Genomovar III
(n p 46)
B. multivorans
(n p 19)
Age (years) at acquisition 17.76  1.11 13.2  0.91 (P p .004)
Duration of infection (years) 2.29  0.38 1.48  0.61 (P p .25)
Transient infection 9 (20) 10 (53)
Cumulative mortality 20 (43)a 3 (16)a
Genomovar III, type 01 4 (44) —
Genomovar III, type 02 5 (55) —
Genomovar III, type 04 11 (70) —
Terminal pulmonary decompensation 12 (26) 1 (5)b
B. cepacia syndrome 6 (13) 1 (5)c
Infected with P. aeruginosa prior to
acquisition of B. cepacia complex 35 (76) 9 (47)
Duration of P. aeruginosa infection
prior to acquisition of B. cepacia
complex 5.4  0.69 5.9  1.15 (P p .70)
a Includes 2 patients who were colonized with both B. multivorans and genomovar III at death.
b Includes 1 patient who was colonized with both B. multivorans and genomovar III at death.
c Includes 1 patient who was colonized with both B. multivorans and genomovar III at death.
vorans–infected patients who became infected with genomovar
III-A strains, 2 are alive but remain chronically infected with
only the acquired genomovar III-A strain, and 1 is alive and
currently B. cepacia complex–negative. Replacement of geno-
movar III-A infection by strains of other genomovars was not
observed during the study period.
DISCUSSION
The clinical course and epidemiology of infection with B. ce-
pacia complex among patients with CF in British Columbia
appear to depend on the specific genomovar with which pa-
tients are infected. Strains of B. cepacia genomovar III were the
most prevalent “novospecies” recovered and were also associ-
ated with epidemic spread, replacement of B. multivorans in-
fection, cases of B. cepacia syndrome and high mortality. In
contrast, evidence of patient-to-patient spread of B. multivorans
was rarely observed over the 17-year study period. One sibling
pair transiently shared the same B. multivorans strain; this is
consistent with infection of CF sibling pairs with P. aeruginosa
[26].
Whiteford et al. [27] reported an outbreak of B. cepacia
among pediatric patients attending a clinic in Glasgow, which
was associated with some deaths. The strain responsible for this
epidemic has recently been classified as B. multivorans (geno-
movar II) [13], and hence the report by Whiteford et al. [27]
contrasts with the lack of evidence of epidemic spread of B.
multivorans in our study. The rapid spread of B. multivorans
and short duration of the Glasgow epidemic [27] suggest that
(1) transmission may have been due to factors other than pa-
tient contact or (2) the particular clone of B. multivorans may
have greater potential for spread than strains we have encoun-
tered. Phylogenetic analysis of the recA gene of the index B.
multivorans strain (C1576) in the Glasgow epidemic indicates
that it is genetically distinct from B. multivorans strains present
in the Vancouver CF population [21]. In agreement with the
findings of Whiteford et al. [27], we observed that B. multi-
vorans infection occurred predominantly in the pediatric CF
patient population. Spread of B. cepacia strains among 4 adult
patients with CF in Cardiff, Wales, was also reported [28]; the
strain responsible for this outbreak was also subsequently found
to be B. multivorans [18].
Finally, Segonds et al. [19] reported epidemic spread of 2 B.
multivorans clones in multiple CF centers involving multiple
patients and several cases of fatal septicemia. However, genetic
typing of the latter strains was performed by PCR-ribotyping
[19], which has limited discriminatory power for B. cepacia [7]
and may have overrepresented the clonality of each outbreak.
The behavior of B. multivorans strains therefore appears to vary
greatly among different CF patient populations, but within the
Vancouver CF patient population it did not present a significant
infection control problem. Lack of nosocomial spread of B.
cepacia strains was also observed in the Danish CF population
[29]; it is interesting that these strains have been found to be
B. multivorans (D. Henry and D. P. Speert, unpublished data),
suggesting that other treatment centers have also encountered
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B. multivorans strains with reduced risk of patient-to-patient
spread. Transient B. multivorans infection was observed in half
of the infected patients, suggesting that therapy may clear this
organism or that it may be shed spontaneously in pediatric
patients; transient infection was rarely observed with strains of
genomovar III.
Genomovar III was the predominant species infecting pa-
tients in our study, corroborating other culture collection–based
observations [13, 18]. Patient-to-patient spread of B. cepacia
among Vancouver patients with CF was also specifically asso-
ciated with genomovar III strains, of the genomovar III-A recA
subgroup [21]. These strains presented a significant infection
control problem, capable of replacing infection with B. mul-
tivorans and leading to poor prognosis. Ledson et al. [30] also
recently reported cross-infection between patients with CF who
were infected with B. cepacia. All 5 cases of cross-infection were
due to a B. cepacia strain that encoded the cable pilus and
belonged to the United Kingdom epidemic strain type [9, 18].
We report that replacement of infection is not solely linked to
the cblA strains; moreover, at our centers it was specifically
associated with genomovar III-A strains [21], which encode the
B. cepacia epidemic strain marker.
Prior to the occurrence of cross-infection, each CF patient
examined by Ledson et al. [30] was infected with a unique B.
cepacia strain; these data concur with our observations. Epi-
demic spread of genomovar III-B strains was not observed
within the Vancouver CF patient population; however, strains
of this genetic lineage have been associated with outbreaks of
infection among patients with CF at several other centers [18].
These data also suggest that strains with the greatest potential
for epidemic spread should now be sought by means of tests
for the identification of genomovar [13, 21]; we observed that
genomovar III-A was an excellent marker of epidemic spread.
Other markers, such as cblA or B. cepacia epidemic strain
marker, which are commonly associated with this “species” type
but of which the natural prevalence and stability among the B.
cepacia complex have not been fully determined, should be
used as well [21].
In conclusion, we present the first systematic study of B.
cepacia complex infection among a defined CF patient popu-
lation. Infection with strains of genomovar III-A was associated
with apparent patient-to-patient spread and high mortality.
Nonetheless, one cannot draw firm conclusions about the at-
tributable risk from infection with genomovar III versus B.
multivorans, since the age of patients in the 2 groups was quite
different. A case-control study to enable risk assessment is cur-
rently under way.
We have not encountered significant clinical or infection
control problems in patients infected with B. multivorans, but
other centers have reported more widespread transmission of
strains of this new species [19, 27, 28]. Because our study is
the first to systematically evaluate a CF patient population for
the genomovar status of B. cepacia infection, it is perhaps too
early to make definitive judgements on the risk that each gen-
omovar poses to patients with CF. However, replacement of B.
multivorans with strains of genomovar III-A is a significant
clinical problem. Other groups have reported this phenomenon
for the cblA genomovar III-A strain [30]. In light of this ap-
parent epidemiological difference between B. multivorans and
genomovar III, we recommend that patients infected with B.
cepacia genomovar III strains should not be cohorted with
patients infected with other genomovars of the B. cepacia
complex.
Acknowledgments
We are grateful to Dr. Nevio Cimolai (British Columbia Chil-
dren’s Hospital Microbiology Laboratory) and Dr. Alison
Clarke (St. Paul’s Hospital Microbiology Laboratory) for pro-
viding access to bacterial isolates recovered from patients’ spu-
tum. We thank Jocelyn Bischof, Gary Probe, Julie Fadden, Tom
Coenye, and Despina Frangolias for excellent technical assis-
tance. E. M. acknowledges the British Columbia Lung Asso-
ciation for provision of a Career Development Award and the
British Columbia Research Institute for Children’s and
Women’s Health for an Investigator Establishment Award.
References
1. Yabuchi E, Kosako Y, Oyaizu H, et al. Proposal of the Burkholderia
gen. nov. and transfer of seven species of the genus Pseudomonas ho-
mology group II to the new genus, with the type species Burkholderia
cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol
1992; 36:1251–5.
2. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in
cystic fibrosis: an emerging problem. J Pediatr 1984; 104:206–10.
3. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid
Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev
1996; 60:539–74.
4. LiPuma JJ. Burkholderia cepacia: management issues and new insights.
Clin Chest Med 1998; 19:473–86.
5. Sajjan US, Sun L, Goldstein R, Forstner JF. Cable (Cbl) type II pili of
cystic fibrosis–associated Burkholderia (Pseudomonas) cepacia: nucle-
otide sequence of the cblA major subunit pilin gene and novel mor-
phology of the assembled appendage fibers. J Bacteriol 1995; 177:
1030–8.
6. Sun L, Jiang R-Z, Steinbach S, et al. The emergence of a highly trans-
missible lineage of cbl Pseudomonas (Burkholderia) cepacia causing
epidemics in North America and Britain. Nature Med 1995; 1:661–6.
7. Mahenthiralingam E, Campbell ME, Henry DA, Speert DP. Epide-
miology of Burkholderia cepacia infection in patients with cystic fibrosis:
analysis by random amplified polymorphic DNA (RAPD) fingerprint-
ing. J Clin Microbiol 1996; 34:2914–20.
8. Mahenthiralingam E, Simpson DA, Speert DP. Identification and char-
acterization of a novel DNA marker associated with epidemic strains
of Burkholderia cepacia recovered from patients with cystic fibrosis. J
Clin Microbiol 1997; 35:808–16.
9. Govan JRW, Brown PH, Maddison J, et al. Evidence for transmission
 at Acquisitions on Septem
ber 12, 2011
cid.oxfordjournals.org
D
ow
nloaded from
 
B. cepacia Infection in Patients with CF • CID 2001:33 (1 November) • 1475
of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet
1993; 342:15–9.
10. Hutchinson GR, Parker S, Pryor JA, et al. Home-use nebulizers: a
potential primary source of Burkholderia cepacia and other colistin-
resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin
Microbiol 1996; 34:584–7.
11. Høiby N. Isolation and treatment of cystic fibrosis patients with lung
infections caused by Pseudomonas (Burkholderia) cepacia and multi-
resistant Pseudomonas aeruginosa. Netherlands J Med 1995; 46:280–7.
12. Fung SK, Dick H, Devlin D, Tullis E. Transmissibility and infection
control implications of Burkholderia cepacia. Can J Infect Dis 1998; 9:
177–82.
13. Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple
genomovars of Burkholderia cepacia in cystic fibrosis patients: proposal
of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997; 47:
1188–200.
14. Ursing JB, Rossello-Mora RA, Garcia-Valdes E, Lalucat J. Taxonomic
note: a pragmatic approach to the nomenclature of phenotypically
similar genomic groups. Int J Syst Bacteriol 1995; 45:604.
15. Vandamme P, Mahenthiralingam E, Holmes B, et al. Identification and
population structure of Burkholderia stabilis sp. nov (formerly Burk-
holderia cepacia genomovar IV). J Clin Microbiol 2000; 38:1042–7.
16. Corey M, Farewell V. Determinants of mortality from cystic fibrosis
in Canada, 1970–1989. Am J Epidemiol 1996; 143:1007–17.
17. Henry DA, Campbell ME, LiPuma JJ, Speert DP. Identification of
Burkholderia cepacia from patients with cystic fibrosis and a new se-
lective medium for its isolation. J Clin Microbiol 1997; 35:614–9.
18. Mahenthiralingam E, Coenye T, Chung J, et al. A diagnostically and
experimentally useful panel of strains from the Burkholderia cepacia
complex. J Clin Microbiol 2000; 38:910–3.
19. Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of Burk-
holderia species by PCR–restriction fragment length polymorphism
analysis of the 16S rRNA gene and application to cystic fibrosis isolates.
J Clin Microbiol 1999; 37:2201–8.
20. Frangolais DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia
in cystic fibrosis: variable disease course. Am J Respir Crit Care Med
1999; 160:1572–7.
21. Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-based diagnostic
approaches for the identification of Burkholderia cepacia complex bac-
terial pathogens: Burkholderia vietnamiensis, Burkholderia multivorans,
Burkholderia stabilis, Burkholderia cepacia genomovar I and Burkhold-
eria cepacia genomovar III. J Clin Microbiol 2000; 38:3165–73.
22. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. Ran-
dom amplified polymorphic DNA typing of Pseudomonas aeruginosa
isolates recovered from patients with cystic fibrosis. J Clin Microbiol
1996; 34:1129–35.
23. Steinbach S, Sun L, Jiang R-Z, et al. Pseudomonas cepacia in cystic
fibrosis lung transplant recipients and clinic patients. N Engl J Med
1994; 331:981–7.
24. Cheng H-P, Lessie TG. Multiple replicons constituting the genome of
Pseudomonas cepacia 17616. J Bacteriol 1994; 176:4034–42.
25. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal
DNA restriction patterns produced by pulsed-field gel electrophoresis:
criteria for bacterial strain typing. J Clin Microbiol 1995; 33:2233–9.
26. Grotheus D, Koopmann V, von der Hardt H, Tu¨mmler B. Genome
fingerprinting of Pseudomonas aeruginosa indicates colonization of cys-
tic fibrosis siblings with closely related strain. J Clin Microbiol 1988;
26:1973–7.
27. Whiteford ML, Wilkinson JD, McColl JH, et al. Outcome of Burk-
holderia (Pseudomonas) cepacia colonization in children with cystic
fibrosis following a hospital outbreak. Thorax 1995; 50:1194–8.
28. Millar-Jones L, Ryley HC, Paull A, Goodchild MC. Transmission and
prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients. Resp
Med 1998; 92:178–83.
29. Ryley H, Ojeniyi B, Høiby N, Week J. Lack of nosocomial cross-in-
fection by Burkholderia cepacia in Danish cystic fibrosis patients. Eur
J Clin Microbiol Dis 1996; 15:755–8.
30. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ. Cross
infection between cystic fibrosis patients colonized with Burkholderia
cepacia. Thorax 1998; 53:432–6.  at Acquisitions on Septem
ber 12, 2011
cid.oxfordjournals.org
D
ow
nloaded from
 
